Table 3.

Linear regression analysis for DKK3 concentrations in the verification cohort

Factor	n	Simple regression		Multiple regression
		Fold difference* (95% CI)	P	Fold difference* (95% CI)	P
Main comparison			<.001†		<.001†
No GVHD	62	Reference		Reference
Chronic GVHD without steroid	37	1.40 (1.21-1.63)	<.001	1.40 (1.21-1.61)	<.001
Chronic GVHD with steroid	87	1.84 (1.63-2.07)	<.001	1.83 (1.63-2.05)	<.001
Patient age at sample, continuous (per decade)	186	1.08 (1.03-1.13)	.003	1.07 (1.03-1.12)	.001
Patient sex
Male	96	Reference
Female	90	0.99 (0.87-1.13)	.92
Race
White	167	Reference
Others	19	0.92 (0.74-1.14)	.45
Stem cell source			.06†
Peripheral blood stem cell	162	Reference
Bone marrow	18	0.82 (0.66-1.03)	.083
Cord blood	5	0.65 (0.44-0.97)	.035
Missing	1	0.74 (0.31-1.80)	.51
Conditioning intensity
Myeloablative	96	Reference
Reduced intensity	90	1.17 (1.03-1.33)	.02
Donor type			.29†
HLA-matched relative	68	Reference
HLA-mismatched relative	7	0.94 (0.66-1.34)	.75
Unrelated donor	111	1.10 (0.96-1.27)	.16
Female donor to a male recipient	37	1.05 (0.89-1.24)	.57
Prior grade 2-4 acute GVHD	108	0.99 (0.86-1.13)	.84
Duration from HCT to sample draw per y	186	1.08 (1.02-1.15)	.007
NIH global severity			<.001†
None or mild	101	Reference
Moderate	35	1.41 (1.20-1.66)	<.001
Severe	50	1.51 (1.31-1.75)	<.001
Involved sites
Skin	74	1.40 (1.24-1.58)	<.001
Mouth	58	1.34 (1.17-1.54)	<.001
Eye	72	1.51 (1.34-1.71)	<.001
Gastrointestinal tract	24	1.32 (1.09-1.60)	.005
Liver	5	1.24 (0.83-1.86)	.29
Lung (bronchiolitis obliterans)	4	1.38 (0.88-2.16)	.16
Joint/fascia	57	1.38 (1.21-1.58)	<.001
Genital	15	1.15 (0.91-1.47)	.24

CI, confidence interval.

^*Fold difference values represent the anti-log₁₀ of the regression coefficient.

^†Overall P value.